Clinical Trials Logo

Clinical Trial Summary

This phase II trial studies the effect of atezolizumab and bevacizumab before surgery in treating patients with liver cancer that can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Giving the combination of atezolizumab and bevacizumab may help to prevent liver cancer from returning after surgery.


Clinical Trial Description

PRIMARY OBJECTIVES: 1. To evaluate safety and tolerability of atezolizumab plus bevacizumab combination therapy in the pre-operative setting. 2. To assess the rate of pathologic complete response. SECONDARY OBJECTIVE: To evaluate the correlation between rate of pathologic complete response, overall response rate at time of surgery (per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 and modified RECIST 1.0), duration of response as defined by time to recurrence/recurrence-free survival, in addition to overall survival. EXPLORATORY OBJECTIVES: 1. Evaluate the predictive value of dynamic changes in fibrosis stage. Fibrosis stage will be assessed by histology by on serial tissue samples collected at baseline and at time of surgery (at 12 weeks after treatment begins). 2. To measure baseline and longitudinal changes of immune infiltration including CD8/Treg ratio and CD68+ density. 3. To explore the association between PD-L1 (and PD-L2) expression by immunohistochemistry, RNA seq genomic profiling, and antitumor efficacy 4. To evaluate baseline and longitudinal changes of tumor-necrosis factor (TNF)-α, pSTAT3, and c- MET; immune cell density such as frequency of PD-1+4-1BB+ CD8 T cells, pro-inflammatory cytokines, and hepatic fibrosis markers (APRI, FIB-4, hyaluronic acid, FibroTest [FibroSure]), non- alcoholic-fatty-liver-disease (NAFLD) fibrosis score (NFS), and enhanced liver fibrosis test (ELF)] as biomarkers of response to therapy. 5. To assess the impact of therapy on the diversity of the tumor-specific T-cell repertoire 6. To explore the correlation between immunological and molecular changes in tumor tissues and peripheral blood with TTP, time to recurrence, OS, and rate of AEs. In particular, we will evaluate the potential of pre-treatment CD8 T-cell density, PD-L1 expression, and CD68 to CD8 ratio or circulating CD68+DR-/low density to predict responsiveness to checkpoint blockade. OUTLINE: Patients receive atezolizumab intravenously (IV) over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery during week 12. After completion of study treatment, patients are followed up every 3 months for 2 years. ;


Study Design


Related Conditions & MeSH terms

  • Carcinoma
  • Carcinoma, Hepatocellular
  • Resectable Hepatocellular Carcinoma
  • Stage I Hepatocellular Carcinoma AJCC v8
  • Stage IA Hepatocellular Carcinoma AJCC v8
  • Stage IB Hepatocellular Carcinoma AJCC v8
  • Stage II Hepatocellular Carcinoma AJCC v8

NCT number NCT04721132
Study type Interventional
Source M.D. Anderson Cancer Center
Contact Maen Abdelrahim
Phone 713-441-9948
Email mabdelrahim@houstonmethodist.org
Status Recruiting
Phase Phase 2
Start date February 10, 2021
Completion date December 31, 2027

See also
  Status Clinical Trial Phase
Completed NCT03222076 - Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer Phase 2
Recruiting NCT04856046 - Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer
Completed NCT01522820 - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Phase 1
Recruiting NCT04857684 - SBRT + Atezolizumab + Bevacizumab in Resectable HCC Early Phase 1
Recruiting NCT04701060 - Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma Phase 2
Not yet recruiting NCT05578430 - AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING) Phase 2
Recruiting NCT02379377 - 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant Phase 1
Completed NCT06013657 - Surgical Resection for Hepatocellular Carcinoma
Recruiting NCT05519410 - Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma Phase 2
Not yet recruiting NCT04834986 - Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma Phase 2
Recruiting NCT05701488 - SIRT With Tremelimumab and Durvalumab for Resectable HCC Phase 1
Withdrawn NCT04965714 - Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer Phase 2
Not yet recruiting NCT05807776 - Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma. Phase 2